Payment overview · 2025
General Payments
$4,771.75
55 reported records · 14 companies
Healthcare provider profile · identity verified
Jerry L Jurado, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · UNION CITY, NJ · NPI 1720004021
Verified facts
What the public records show
CMS Open Payments records show Jerry L Jurado, M.D. received $4,771.75 in general payments during 2025 across 55 reported records.
AstraZeneca Pharmaceuticals LP accounted for 25.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 261 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lokelma by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 239 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synjardy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 239 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 304 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 212 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $1,228.37 | 25.7% | 13 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $1,163.82 | 24.4% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $407.29 | 8.5% | 15 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $387.80 | 8.1% | 4 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $259.75 | 5.4% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $249.99 | 5.2% | 2 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $248.12 | 5.2% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $243.40 | 5.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $239.89 | 5.0% | 2 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $160.33 | 3.4% | 1 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $125.00 | 2.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $20.88 | 0.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.42 | 0.4% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $17.69 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,755.76 | 54 |
| Education | $15.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $1,163.82 | 8 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $1,163.82 | 8 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $1,163.82 | 8 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $407.29 | 15 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $355.48 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $352.42 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $343.51 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $262.80 | 3 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $259.75 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $249.99 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $243.40 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $239.89 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $163.72 | 13 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $160.33 | 1 | 2025 |
Source payment records
|
|||||
| BIOMONITOR Normalized: biomonitor |
Device | BIOTRONIK INC. | $133.60 | 2 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| AMVIA EDGE Normalized: amvia edge |
Device | BIOTRONIK INC. | $114.52 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $20.88 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.42 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.42 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $17.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 261 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 239 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 88 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 304 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
17 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
261 | 103 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
239 | 89 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
239 | 89 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
88 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
55 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
304 | 83 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
212 | 65 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 927 | 346 |
| Metformin Hcl | Metformin Hcl | 509 | 240 |
| Ezetimibe | Ezetimibe | 507 | 219 |
| Atorvastatin Calcium | Atorvastatin Calcium | 490 | 185 |
| Metoprolol Succinate | Metoprolol Succinate | 412 | 165 |
| Amlodipine Besylate | Amlodipine Besylate | 390 | 161 |
| Losartan Potassium | Losartan Potassium | 326 | 129 |
| Ozempic | Semaglutide | 304 | 83 |
| Fluticasone Propionate | Fluticasone Propionate | 301 | 148 |
| Januvia | Sitagliptin Phosphate | 298 | 96 |
| Diclofenac Sodium | Diclofenac Sodium | 280 | 100 |
| Farxiga | Dapagliflozin Propanediol | 261 | 103 |
| Levothyroxine Sodium | Levothyroxine Sodium | 252 | 91 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 240 | 97 |
| Jardiance | Empagliflozin | 239 | 89 |
| Vascepa | Icosapent Ethyl | 232 | 88 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 228 | 68 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 227 | 80 |
| Alendronate Sodium | Alendronate Sodium | 219 | 85 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 216 | 72 |
| Tamsulosin Hcl | Tamsulosin Hcl | 214 | 81 |
| Rybelsus | Semaglutide | 212 | 65 |
| Omeprazole | Omeprazole | 204 | 87 |
| Lidocaine | Lidocaine | 199 | 76 |
| Telmisartan | Telmisartan | 193 | 67 |
| Pioglitazone Hcl | Pioglitazone Hcl | 192 | 107 |
| Pantoprazole Sodium | Pantoprazole Sodium | 191 | 83 |
| Allopurinol | Allopurinol | 179 | 69 |
| Hydralazine Hcl | Hydralazine Hcl | 173 | 55 |
| Famotidine | Famotidine | 171 | 85 |
| Gabapentin | Gabapentin | 168 | 67 |
| Montelukast Sodium | Montelukast Sodium | 166 | 67 |
| Trazodone Hcl | Trazodone Hcl | 154 | 58 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 147 | 76 |
| Naproxen | Naproxen | 146 | 81 |
| Meloxicam | Meloxicam | 144 | 64 |
| Carvedilol | Carvedilol | 124 | 46 |
| Ammonium Lactate | Ammonium Lactate | 116 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 115 | 45 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 112 | 30 |
| Azithromycin | Azithromycin | 110 | 94 |
| Linzess | Linaclotide | 103 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 101 | 43 |
| Lisinopril | Lisinopril | 101 | 44 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 101 | 38 |
| Icosapent Ethyl | Icosapent Ethyl | 100 | 44 |
| Eliquis | Apixaban | 94 | 25 |
| Repatha Sureclick | Evolocumab | 89 | 36 |
| Mounjaro | Tirzepatide | 88 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 87 | 29 |
| Xarelto | Rivaroxaban | 86 | 31 |
| Kerendia | Finerenone | 85 | 30 |
| Ipratropium Bromide | Ipratropium Bromide | 83 | 43 |
| Alprazolam | Alprazolam | 81 | 22 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 80 | 41 |
| Valsartan | Valsartan | 75 | 32 |
| Donepezil Hcl | Donepezil Hcl | 71 | 30 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 70 | 23 |
| Ibuprofen | Ibuprofen | 70 | 30 |
| Tradjenta | Linagliptin | 65 | 31 |
| Clobetasol Propionate | Clobetasol Propionate | 62 | 24 |
| Furosemide | Furosemide | 60 | 30 |
| Metformin Hcl Er | Metformin Hcl | 60 | 27 |
| Clonazepam | Clonazepam | 59 | 17 |
| Hydrocortisone | Hydrocortisone | 58 | 31 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 55 | 46 |
| Trulicity | Dulaglutide | 55 | 19 |
| Simvastatin | Simvastatin | 53 | 20 |
| Meclizine Hcl | Meclizine Hcl | 52 | 29 |
| Ztlido | Lidocaine | 52 | 14 |
| Finasteride | Finasteride | 47 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 45 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | 14 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 41 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 17 |
| Ketoconazole | Ketoconazole | 37 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 36 | 17 |
| Terconazole | Terconazole | 34 | 18 |
| Atenolol | Atenolol | 33 | 12 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 32 | 32 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 18 |
| Lorazepam | Lorazepam | 32 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 31 | 21 |
| Bydureon Bcise | Exenatide Microspheres | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 25 |
| Dapagliflozin | Dapagliflozin Propanediol | 30 | 12 |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 24 |
| Tramadol Hcl | Tramadol Hcl | 29 | 11 |
| Bupropion Xl | Bupropion Hcl | 28 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Potassium Chloride | Potassium Chloride | 28 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | 22 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | 11 |
| Steglatro | Ertugliflozin Pidolate | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | 12 |
| Memantine Hcl | Memantine Hcl | 26 | 11 |
| Valacyclovir | Valacyclovir Hcl | 26 | suppressed |
| Repatha Syringe | Evolocumab | 25 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 23 | 13 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 22 | 21 |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | 13 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Procto-Med Hc | Hydrocortisone | 20 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Methimazole | Methimazole | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | 12 |
| Mupirocin | Mupirocin | 19 | 15 |
| Sucralfate | Sucralfate | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Segluromet | Ertugliflozin/Metformin | 18 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 18 | suppressed |
| Hydroxyurea | Hydroxyurea | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Prolia | Denosumab | 17 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Pure Comfort Alcohol Pad | Alcohol Antiseptic Pads | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Alogliptin | Alogliptin Benzoate | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 14 |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Alcohol Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 14 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 13 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 11 | 11 |
| Celecoxib | Celecoxib | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,771.75 · 55 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AMVIA EDGE, APRETUDE, BIOMONITOR, BREZTRI, Barostim Neo System, FARXIGA, FASENRA, FFRct, GLYCATE, JARDIANCE, LEQVIO, LifeVest, MOUNJARO, NUPLAZID, OTEZLA, Ozempic, RELTONE 200 MG, RELTONE 400 MG, REPATHA, Symbravo, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error